International Stem Cell (ISCO) Non Operating Income (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Non Operating Income of -$35000.0 for Q4 2025, up 12.5% year-over-year from -$31111.1 in Q4 2024, and up 5.41% quarter-over-quarter from -$37000.0 in Q3 2025.
International Stem Cell (ISCO) Non Operating Income (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Non Operating Income for 16 consecutive years, with -$35000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 12.5% year-over-year to -$35000.0; the TTM figure through Dec 2025 stood at -$151000.0 (down 7.09% YoY), while the FY2025 annual figure was -$151000.0, down 7.09% from the prior year.
- Non Operating Income climbed to -$35000.0 in Q4 2025 per ISCO's latest filing, from -$37000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $636000.0 in Q2 2023 and bottomed at -$43000.0 in Q3 2022.
- Historically, Non Operating Income has averaged $55600.0 across 5 years, with a median of -$34500.0 in 2022.
- Annual changes were most pronounced in 2021 — Non Operating Income plunged 333.33% — and 2023, when it soared 2027.27%.
- International Stem Cell's Non Operating Income stood at -$28000.0 in 2021, then tumbled by 35.71% to -$38000.0 in 2022, then advanced by 10.53% to -$34000.0 in 2023, then retreated by 17.65% to -$40000.0 in 2024, then increased by 12.5% to -$35000.0 in 2025.
- Business Quant data shows ISCO's Non Operating Income at -$35000.0 in Q4 2025, -$37000.0 in Q3 2025, and -$38000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | -36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36,000.00 |
| Dec 31, 2025 | -35,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Jun 30, 2025 | -38,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Dec 31, 2024 | -40,000.00 |
| Sep 30, 2024 | -35,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | -34,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Jun 30, 2023 | 636,000.00 |
| Mar 31, 2023 | -36,000.00 |
| Dec 31, 2022 | -38,000.00 |
| Sep 30, 2022 | -43,000.00 |
| Jun 30, 2022 | -33,000.00 |
| Mar 31, 2022 | -34,000.00 |
| Dec 31, 2021 | -28,000.00 |
| Sep 30, 2021 | 458,000.00 |
| Jun 30, 2021 | 622,000.00 |